The redox-senescence axis and its therapeutic targeting
Natalie Y.L. Ngoi(Institut Gustave Roussy), Shazib Pervaiz(National University of Singapore), Marie‐Véronique Clement(National University of Singapore), Stephen Jun Fei Chong(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Angeline QX. Liew(National University of Singapore)
Cited by 83
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595